Project Grant K23HL183845
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $199K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jacksonville, FL 32224, USA
Similar Awards
- Federal Grant Award Summary Mayo Clinic received a $1.34 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025 through May 31, 2029. The award funds research to discover aging-associated genetic modifiers and develop therapies for anthracycline-induced cardiotoxicity (AIC), a cumulative dose-dependent cardiac toxicity that limits the clinical use of anthracycline chemotherapeutic...
- Federal Grant Award Summary Mayo Clinic received a $149,214 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) on September 30, 2025, with completion anticipated by September 23, 2028. The award funds research investigating lipid-loaded macrophages in atherosclerotic plaque inflammation, with the goal of advancing understanding of cardiovascular disease mechanisms. The research will characterize how...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Mayo Clinic a $756,906 project grant (CFDA 93.837 – Cardiovascular Diseases Research) commencing September 1, 2025, and concluding June 30, 2029, to conduct a population-based study of deep learning measures of breast arterial calcification (BAC) for improving women's cardiovascular health using repurposed mammogram images. The research leverages automated artificial intelligence algorithms to...
- Federal Grant Award Summary Mayo Clinic Arizona, through funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is conducting a four-year research project investigating the role of Programmed Cell Death 4 (PDCD4) in doxorubicin-induced cardiotoxicity. The $695,997 project grant, awarded August 18, 2025, and extending through May 31, 2029, focuses on understanding how PDCD4 functions as a cardioprotective molecule...
- Federal Project Grant Award Summary Mayo Clinic received a $739,562 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with performance extending through May 31, 2029. The grant supports research investigating the epigenetic regulation of donor heart preservation mediated by BRD4 (bromodomain and extraterminal domain protein 4), a protein that plays a critical role in cardiac function...
- Federal Grant Award Summary Mayo Clinic received a $783,661 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion scheduled for August 31, 2026. The award funds a pragmatic, randomized clinical trial evaluating the effectiveness and safety of oral midodrine as a vasopressor-sparing agent in patients with sepsis-associated hypotension. The study seeks to reduce intensive...
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $185,760 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 25, 2025, with a completion date of July 31, 2028. This career development award supports research aimed at advancing cardiovascular disease (CVD) risk prediction tools specifically for women, addressing the significant gap that current...
- Federal Project Grant Award Summary Mayo Clinic received a $745,851 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2030. The award supports a five-year research initiative examining the integration of inspiratory muscle training (IMT) into cardiac rehabilitation (CR) protocols for patients with heart failure with reduced ejection fraction (HFrEF). The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Tufts University School of Medicine a $1.12 million Project Grant (CFDA 93.837, Cardiovascular Diseases Research) on September 17, 2025, to conduct a multiethnic and multiomics analysis of longitudinal changes in DNA methylation (DNAM) and cardiovascular health. The four-year research initiative, concluding July 31, 2029, integrates longitudinal epigenome-wide DNAM data with behavioral, clinical, genetic,...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a $249,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for the period June 1, 2026 through April 30, 2029. This award funds research to characterize genetic variants associated with doxorubicin-induced cardiotoxicity (DIC), a life-threatening side effect of chemotherapy used to treat breast cancer and pediatric cancers. The research leverages...